Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00036296 | Effects of Talampanel on Patients With Advanced Parkinson's Disease | PHASE1 | COMPLETED | 22 | — | — | Dec 1, 2006 | Feb 1, 2007 | Apr 13, 2011 | - | — |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | 75mg per day (in 3 doses) Talampanel for 22 days |
| 2 | PLACEBO_COMPARATOR | 3 doses a day for 22 days |
| Name | Type | Description |
|---|---|---|
| talampanel | DRUG | 75mg per day divided into 3 doses for 22 days |
Inclusion Criteria: * Troublesome on-period dyskinesias as defined by a Unified Parkinson's Disease Rating Scale (UPDRS) dyskinesia sub-score \>25% of Duration of dyskinesia during waking hours and 33 must have moderate disability * Lang-Fahn dyskinesia rating score more than 2 for at least two of ...